Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,816 people get CLX articles and Market Currents by email alert.
Get email alerts on CLX »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Marketwire (May 13, 2013)
-
Marketwire (May 7, 2013)
To learn more about Seeking Alpha Pro, click here.
-
Clorox: Which Way From Here?William Rudder • Tue, Feb 26
-
Earnings Preview: The Clorox CompanyVytautas Drumelis • Wed, Aug 1, 2012
-
When It's Time To Sell CloroxDoug Meeks • Fri, Jun 22, 2012
-
The Clorox Company's CEO Hosts 2012 Analyst Day (Transcript)Thu, May 31, 2012 • 1 Comment
-
The Clorox's CEO Discusses Q3 2012 Results - Earnings Call TranscriptWed, May 2, 2012 • 1 Comment
-
Clorox's CEO Discusses Q4 2011 Results - Earnings Call TranscriptWed, Aug 3, 2011
-
Clorox's CEO Discusses Q3 2011 Results - Earnings Call TranscriptTue, May 3, 2011
-
Clorox's CEO Discusses Q2 2011 Results - Earnings Call TranscriptFri, Feb 4, 2011
-
Clorox CEO Discusses F1Q11 Results - Earnings Call TranscriptWed, Nov 3, 2010
-
Clorox F4Q10 (Qtr End 06/30/2010) Earnings Call TranscriptTue, Aug 3, 2010
-
Clorox Q3 2010 Earnings Call TranscriptTue, May 4, 2010 • 1 Comment
-
The Clorox Company F2Q10 (Qtr End 12/31/09) Earnings Call TranscriptThu, Feb 4, 2010
-
Clorox F1Q10 (Qtr End 9/30/09) Earnings Call TranscriptMon, Nov 2, 2009
-
The Clorox Co. F4Q09 (Qtr End 30/06/09) Earnings Call TranscriptMon, Aug 3, 2009
-
The Clorox Company F3Q09 (Qtr End 3/31/09) Earnings Call TranscriptMon, May 4, 2009
-
The Clorox Co. F2Q09 (Qtr End 12/31/08) Earnings Call TranscriptWed, Feb 4, 2009
-
at CNBC.com (May 15, 2013)
-
at CNBC.com (May 14, 2013)
-
Marketwire (May 13, 2013)
-
at CNBC.com (May 7, 2013)
-
Marketwire (May 7, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at CNBC.com (Apr 26, 2013)
-
at CNBC.com (Apr 26, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 11, 2013)
-
Marketwire (Apr 2, 2013)
-
at CNBC.com (Mar 18, 2013)
-
at CNBC.com (Feb 14, 2013)
-
Marketwire (Feb 13, 2013)
-
at CNBC.com (Feb 4, 2013)
-
at CNBC.com (Feb 4, 2013)
-
at CNBC.com (Feb 4, 2013)
-
at Fox Business (Feb 4, 2013)
-
Marketwire (Feb 4, 2013)
CLX vs. ETF Alternatives
Company Description
The Clorox Company is a leading manufacturer and marketer of consumer products with fiscal year 2009 net sales of $5.5 billion. The Company sells its products primarily through mass merchandisers, grocery stores and other retail outlets. It markets some of consumers’ most trusted and recognized... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, January 5, 2012, 10:39 AM Clorox (CLX) buys Aplicare and HealthLink, which make infection control products for the healthcare sector, for a total of $80M-$90M. Clorox says the acquisitions will be slightly dilutive to its 2012 profit but should not affect its plans for dividends or share buybacks. Shares -0.6%. (PR) Comment! [Earnings, M&A]
- Friday, September 23, 2011, 4:49 PM Clorox (CLX) drops 3.8% AH on news of Carl Icahn withdrawing his nominees for the company's board. Icahn had sought to replace Clorox's board with the goal of putting the company up for sale, and barring that, acquiring it for $78/share. Comment! [Consumer, On the Move, M&A]
- Friday, September 2, 2011, 8:50 AM Even as Carl Icahn continues his public fight to acquire Clorox (CLX), many arbitrage traders are giving him low odds of pulling off a deal, in part due to Icahn's offer being contingent on a complete board overhaul. In addition, there's plenty of analyst and investor skepticism about a third party such UL or PG buying Clorox. Comment! [Consumer, M&A]
- Wednesday, August 31, 2011, 10:55 AM Shares of Lionsgate (LGF -4.6%) are lower in the wake of the peace pact with Carl Icahn on concerns about plans for tens of millions of shares to hit the market, but Wall Street generally seems pleased. Cowen views it as "an overall significant positive for LGF shares. The sale will remove the overhang of Icahn’s position and [puts] the dispute behind." Comment! [M&A]
- Tuesday, August 30, 2011, 5:57 PM Clorox (CLX) responds to Carl Icahn's bid to buy the company if his director candidates aren't approved: "The Clorox board of directors remains open to any credible proposal, and believes that Mr. Icahn's latest proposal is highly conditional, substantially undervalues the company and is not credible." Comment! [M&A, Consumer]
- Tuesday, August 30, 2011, 2:49 PM Carl Icahn says he would buy Clorox (CLX +2.2%) for $10.3B, or $78/share, if his director candidates are approved and the company isn't sold. If a slate of directors he nominated for the Clorox 2011 annual meeting is elected, Icahn says they would "immediately commence a comprehensive auction process to sell the company." Comment! [M&A, Consumer]
- Wednesday, August 3, 2011, 1:57 PM Clorox's (CLX -1.1%) good quarter is bad news for Carl Icahn, which makes Clorox “accepting Icahn’s offer even less likely than before,” Oppenheimer's Joe Altobello says. Icahn offered to buy Clorox to force a sale of the company to anyone but him, but the better the company’s performance, the lower the odds of a buyout. 1 Comment [Consumer, M&A, Earnings]
- Tuesday, July 26, 2011, 4:43 PM Clorox's (CLX) board rejects Carl Icahn's revised $80/share bid, saying the proposal is "inadequate and unlikely to be completed... lacks detail and contains significant conditionality." Comment! [M&A, Consumer]
- Friday, July 22, 2011, 10:16 AM Eddy Elfenbein thinks the Clorox (CLX) board will turn down Carl Icahn's $80/share bid, even though it overvalues the company; Wall Street expects $4.06 in 2011 EPS, valuing CLX at a "too rich" 20x forward earnings. Doubting that such an offer will come again soon, Elfenbein says "If I were a CLX shareholder, I’d get out of the stock right now." Comment! [M&A, Consumer, Quick Ideas]
- Wednesday, July 20, 2011, 11:18 AM Carl Icahn, now offering to buy Clorox (CLX +3.5%) for $80/share instead of $76.50, doesn't like anyone questioning his seriousness, as he scorches the Clorox board in a letter that includes an offer of $5.2B in escrow, insults hurled at CEO Don Knauss, and various ANGRY ALL CAPS rants. He may have a point: CLX has been trading at 2006 levels. 4 Comments [Consumer, M&A]
- Wednesday, July 20, 2011, 8:24 AM Marketwatch reports Carl Icahn is raising his bid for Clorox (CLX) to $80/share, from a prior level of $76.50. CLX +4.6% premarket. Comment! [Consumer, M&A, On the Move]
- Monday, July 18, 2011, 5:53 PM Clorox's (CLX) board rebuffs Carl Icahn's $76.50/share proposal, calling it "neither credible nor adequate," and sets up a shareholder rights plan that effectively blocks anyone from taking over the company without permission. However, the board says it “remains open to considering any credible plan to create significant stockholder value.” CLX -0.4% AH. 1 Comment [M&A, Consumer]
- Monday, July 18, 2011, 2:58 PM Clorox (CLX -2.1%) shares slip after investors take the weekend to digest Carl Icahn’s $76.50/share proposal for the company. Bernstein Research sounds the alarm for investor caution, acknowledging downside risks if the deal falls apart, given "the real possibility that Icahn is not entirely serious, particularly if the board tries to negotiate aggressively." Shares now at ~$73. Comment! [M&A, On the Move]
- Friday, July 15, 2011, 4:50 PM Chris Stuart questions whether Clorox (CLX +8.9%) is really worth $100/share, as Carl Icahn claims it would be to a potential acquirer such PG, UL, CL, or KMB. At $100, Clorox, which recently forecast FY2012 growth of just 1-3%, would trade at nearly 25x its estimated FY2012 EPS. 1 Comment [M&A, Consumer, On the Move, Top Stories]
- Friday, July 15, 2011, 11:13 AM The Street seems skeptical about Carl Icahn's intentions in his $76.50/share bid for Clorox (CLX), as shares that had traded near the offer price premarket are now only +7.2% at ~$73.40. Investors may be questioning whether Icahn merely wants to boost the price of the stock, of which he owns 9.4%, or whether he is really serious about getting a deal done. 1 Comment [M&A, On the Move]
- Friday, July 15, 2011, 6:25 AM Icahn notes Clorox (CLX) "will not come close" to meeting sales growth forecasts of 3-5%/year. His offer is an attempt to prod CLX to pursue a deal with a "strategic buyer" (PG, UN, CL, KMB, Reckitt Benckiser, Henkel) - who Icahn believes will pay a higher price. "Quite simply, there are few strategic opportunities like Clorox." 1 Comment [M&A, Consumer]
-
Dividend Growth Investor
Clorox Hikes Dividends, but is it a buy at current levels? http://bit.ly/13Bmcz4 $CLX - View all 0 replies
-
- View all 5 replies
-
wigit5: seems my bid set a floor on clx today... never broke through 87.20 on my screen. -
-
- View all 16 replies
-
wigit5: If I could predict the crash yes going to cash would be obvious.. but I'm keeping about 20% of my investment funds in cash at the moment in -
-
Kapitall
3 S&P500 dividend stocks with encouraging accounting trends $D $ITW $CLX http://seekingalpha.com/a/s6a7 - View all 0 replies
LATEST REPLIES
-
- View all 5 replies
-
wigit5: seems my bid set a floor on clx today... never broke through 87.20 on my screen. -
-
- View all 16 replies
-
wigit5: If I could predict the crash yes going to cash would be obvious.. but I'm keeping about 20% of my investment funds in cash at the moment in -
-
neobliviscar
NKE stumble. CLX bleached. MO smoked. BMY took the blue pill. Several of the utilities short circuited today. Hard day for the Reliables. - View all 9 replies
-
-
-
- View all 8 replies
-
-
Ocean Man: I am fortunate to have caught that coal jump. That stuff had some scary moments in 2011.
-
- View all 13 replies
-
Chines33: Difference is I bought most of them especially the oils 20% lower from where they bought them -
-
- View all 3 replies
-
GOLLIATH: I follow the master, the best of the best, Chines. Chines beats you hand down. He has been the best trader here. -
nasalpancho: I have to admit -- even though you are a troll you are rather amusing.
-
- View all 8 replies
-
-
Hillbilly Stock Star: CJES.......good news or M&A could equal lift-off with 60% short, Long 100 shares CJES.







